10 Results for "

MPNs

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "MPNs" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-50856A
CAS No.: 941685-37-6
Synonyms: S-Ruxolitinib; S-INCB18424
Target:  

JAK

Research Areas:  

Cancer

Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-123981
CAS No.: 47208-82-2
Purity:  99.72%
Target:  

Phosphatase

Research Areas:  

Cancer

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site (Ki=8.6 μM). 5MPN does not inhibit PFK-1 or PFKFB3. 5MPN targets the sugar metabolism of tumors and suppresses proliferation of multiple human cancer cell lines .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-157362
Synonyms: TSB
Tryptone Soya Broth can be used for MPN determination of Staphylococcus aureus. Tryptone Soya Broth ingredients include tryptone, soy peptone, sodium chloride, dipotassium hydrogen phosphate, and glucose .
loading...
    loading...
Cat. No.: HY-124727
CAS No.: 2138488-38-5
Purity:  99.51%
Target:  

JAK Apoptosis

Research Areas:  

Cancer

ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM. ZT55 inhibits the proliferation of JAK2 V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia .
loading...
    loading...
Cat. No.: HY-175684
CAS No.: 3087335-24-5
Target:  

JAK STAT Apoptosis

Research Areas:  

Cancer

JAK2-IN-14 is an orally active JAK2 inhibitor with an IC50 of 2 nM. JAK2-IN-14 demonstrates 89.5-, 80.5-, and 51-fold selectivity over JAK1, JAK3, and TYK2, respectively. JAK2-IN-14 inhibits STAT5 signaling pathway. JAK2-IN-14 causes tumor cell cycle arrest and apoptosis. JAK2-IN-14 can used for the study of myeloproliferative neoplasms (MPNs) .
loading...
    loading...
Cat. No.: HY-186043
CAS No.: 2654080-48-3
Research Areas:  

Metabolic Disease Cancer

Menin-MLL-IN-35 (compound 286) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.096 μM in MEIS1 mRNA expression. Menin-MLL-IN-35 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes .
loading...
    loading...
Cat. No.: HY-186044
CAS No.: 2654078-52-9
Research Areas:  

Metabolic Disease Cancer

Menin-MLL-IN-36 (compound 398) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.043 μM in MEIS1 mRNA expression. Menin-MLL-IN-36 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes .
loading...
    loading...
Cat. No.: HY-174430
CAS No.: 1558007-80-9
Research Areas:  

Cancer

WWQ-131 is a potent selective JAK2 inhibitor with an IC50 of 2.56 nM. WWQ-131 shows >252-fold selectivity over JAK1, JAK3, and TYK2. WWQ-131 exhibits antiproliferative activity against cancer cells. WWQ-131 is the ligand for target protein for PROTAC JAK2 degrader-1 (HY-174428). WWQ-131 can be used for the research of myeloproliferative neoplasms (MPNs) .
loading...
    loading...
Cat. No.: HY-182002
Target:  

Apoptosis IAP

Research Areas:  

Cancer

Apoptosis inducer 61 (Compound 4E) is an Apoptosis inducer. Apoptosis inducer 61 significantly downregulates the expression of BIRC3 and activates Apoptosis. Anticancer agent 313 exhibits anticancer activity against ER + breast cancer cells, triple-negative breast cancer cells, and gastric cancer cells .
loading...
    loading...
Cat. No.: HY-P991888

Target:  

STAT

Research Areas:  

Cardiovascular Disease Cancer

INCA033989 is a fully human IgG1 monoclonal antibody targeting mutCALR (KD = 1.75 nM for mutCALR del52; KD = 6.78 nM for mutCALR ins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .
loading...
    loading...